Tarlatamab in SCLC | DeLLphi-301 Phase 2 Trial Results by Brain Metastasis Status | ASCO 2024
Автор: Cancer Research and Statistic Foundation
Загружено: 2025-07-08
Просмотров: 35
Описание:
This video presents results from the DeLLphi-301 Phase 2 trial evaluating Tarlatamab in small cell lung cancer (SCLC), with a special focus on efficacy and safety outcomes based on the presence or absence of brain metastases.
🧠 Tarlatamab is a DLL3-targeting bispecific T-cell engager (BiTE), showing promise in treatment-refractory SCLC.
📈 This data, presented at ASCO 2024, adds to the growing body of evidence supporting targeted immunotherapy in hard-to-treat cancers like SCLC.
🎯 Ideal for: Oncologists, researchers, students, and professionals following immunotherapy developments.
🔔 Subscribe for more expert summaries of clinical trials and breakthrough cancer therapies.
#Tarlatamab #DeLLphi301 #SCLC #BrainMetastasis #ASCO2024 #Immunotherapy #DLL3 #OncologyTrials
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
![Пожалуй, главное заблуждение об электричестве [Veritasium]](https://imager.clipsaver.ru/6Hv2GLtnf2c/max.jpg)
